Tolerability and Background Fluorescence of the MediBeacon Transdermal GFR Measurement System

Acute Kidney Injury Clinical Trial

Official title:

A Study of Tolerability and Background Fluorescence of the MediBeacon Transdermal GFR Measurement System

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03810833
• Other study ID #: ORFM Sensor 100-01
• Status: Completed
• Phase: N/A
• Start date: September 16, 2019
• Est. completion date: September 23, 2019

Study information

• Verified date: January 2020
• Source: MediBeacon
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is designed to evaluate background fluorescence of participants of different ages, gender, and skin color. In addition, 48-hour tolerability of the sensor and adhesive will be evaluated.

Description:

The MediBeacon Transdermal GFR Measurement System investigational is intended to measure the Glomerular Filtration Rate (GFR) in patients with normal or impaired renal function by noninvasively monitoring fluorescent light emission from an exogenous tracer agent (MB-102) over time. The device utilized in this study is the Brilliance device. Approximately 1 male and 1 female from each age cohort (18-50 years; 51+ years) and clustered Fitzpatrick Skin Scale groups (I-II [Light, pale white; white, fair]; III-IV [Medium, white to olive; olive, moderate brown]; and V-VI [Brown, dark brown; black, very dark brown to black]) will be recruited, for a total of 12 participants. Participants will have Brilliance device sensors placed on two locations on their skin, which will remain for 48 hours. The sensor location will be prepared through shaving and cleaning (as applicable), placed on the skin via standard single-use adhesive pads, and baseline measurements collected. Participants may undergo activities of daily living while measurements are being collected. Light pressure and other minor perturbations may be applied to the sensors to evaluate the effect on background fluorescence. Adverse events associated with sensor placement (such as skin irritations) will be recorded.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: September 23, 2019
• Est. primary completion date: September 23, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• Healthy male and female adults age 18 and older

• 2 age cohorts to be recruited: 18 - 50 years of age and 51+ years or older

• Skin color groups to be recruited in accordance with the Fitzpatrick Skin Scale (I - VI)

• Participants willing to sign the Institutional Review Board (IRB) approved informed consent form prior to the initiation of any study specific procedures.

Exclusion Criteria:

• History of skin sensitivity to adhesives (e.g. Band-Aids, surgical tape)

• Any characteristics which, in the opinion of the investigator, makes the participant a poor candidate for participation in the clinical trial

• Significant scarring, tattoos or alterations in pigmentation on the standardized sensor locations that would alter sensor readings versus other areas of the skin

Related Conditions & MeSH terms

• Acute Kidney Injury

Intervention

Device:
• Brilliance device sensor
Two separate sensors will be attached via standard, single-use adhesive pads to the left and right pectoralis major on each participant.

Locations

Country	Name	City	State
United States	St. Louis Clinical Trials	Saint Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
MediBeacon

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean Background Fluorescence	Two separate Brilliance device sensors will be attached via standard adhesive pads to the left and right pectoralis major on each participant. Fluorescence measurements will be collected directly by the MediBeacon Transdermal GFR Measurement System Brilliance device, and will be continuously collected throughout the 48 hour study.	From the time of sensor placement to 48 hours after placement